Dosing chart / Weight & metabolic
Retatrutide vs Survodutide
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| Retatrutide | Survodutide | |
|---|---|---|
| Status | Clinical trials | Clinical trials |
| Also known as | LY3437943 | BI 456906 |
| Typical dose | 1–12 mg | 0.6–6 mg |
| How often | Weekly | Weekly |
| Schedule | Once weekly in trials, escalated stepwise from a low starting dose. | Once weekly in trials, escalated over several months. |
| Daily equivalent | ≈ 0.14–1.7 mg/day | ≈ 86–857 mcg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | Trials ran 48–80 weeks | Trials ran 46–76 weeks |
| Notes | Triple agonist (GLP-1, GIP, glucagon) in Phase 3. Not approved anywhere; any product sold now is unregulated. | Glucagon/GLP-1 dual agonist in Phase 3 for obesity and fatty liver disease. Not approved. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the Retatrutide and Survodutide pages.
Advertisement